The vast majority of deadly lung cancer cases (85 percent) are termed non-small-cell lung carcinomas (NSCLCs), which often contain a mutated gene called LKB1. Researchers have now discovered precisely why inactive LKB1 results in cancer development. The surprising results highlight how LBK1 communicates with two enzymes that suppress inflammation in addition to cell growth, to block tumor growth. The findings could lead to new therapies for NSCLC.
Two therapeutic targets identified for deadly lung cancer
Related Posts
Order Antibiotics online
June 8, 2024Buying antibiotics online
June 8, 2024How do antibiotics work?
June 8, 2024Flagyl: a beacon of hope in the fight against trichomoniasis
February 17, 2024
About admin
Now Dr. Jack Straw is in charge of the website, and organizes it so that medical care is available to everyone. In addition, he is an active member of the medical community, regularly attending international conferences and sharing his experience and knowledge.
Dr. Straw is not only a medical professional and website manager, but also a loving husband and father of his beautiful children.
View all posts by admin →